Prosecution Insights
Last updated: May 29, 2026
Application No. 18/246,393

METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER

Final Rejection §112
Filed
Mar 23, 2023
Priority
Sep 24, 2020 — JP 2020-159460 +1 more
Examiner
LEWIS, PATRICK T
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sumitomo Chemical Co., Ltd.
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
851 granted / 1146 resolved
+14.3% vs TC avg
Moderate +14% lift
Without
With
+14.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
25 currently pending
Career history
1176
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
55.8%
+15.8% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
12.5%
-27.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1146 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s Response Dated January 23, 2026 In the Response dated January 23, 2026, claim 1 was amended. Claims 1-38 are pending. An action on the merits of claims 1-38 is contained herein. The rejection of claims 1-5 and 7-38 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, has been rendered moot in view of applicant’s amendment dated January 23, 2026. The rejection of claim 6 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is maintained for the reasons of record as set forth in the Office Action dated October 23, 2025. The provisional rejection of claims 1, 5-16, and 22 on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of copending Application No. 17/767,825 (reference application) is maintained for the reasons of record as set forth in the Office Action dated October 23, 2025. The provisional rejection of claims 2-4, 17-21, and 23-34 on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of copending Application No. 17/767,825 in view of Wada et al. US 2013/0184450 A1 (Wada) and NIPPON ZEON KK JP 60-105692 A (NIPPON) in combination has been withdrawn in view of applicant’s argument(s) regarding deprotection of the protecting group at the 2’ position inside vs outside of the automated synthesizer (see page 14) and predictability of the art (see page 16). The rejection of claims 1-38 under 35 U.S.C. 103 as being unpatentable over Wada et al. US 2013/0184450 A1 (Wada) and NIPPON ZEON KK JP 60-105692 A (NIPPON) in combination has been withdrawn in view of applicant’s argument(s) regarding deprotection of the protecting group at the 2’ position inside vs outside of the automated synthesizer (see page 14) and predictability of the art (see page 16). Rejections Set Forth in the Office Action Dated October 23, 2025 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim 6 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. No arguments or amendment(s) were set forth by applicant regarding claim 6. Thus, the rejection is maintained for the reasons of record as set forth in the Office Action dated October 23, 2025. Claims 1, 5-16, and 22 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of copending Application No. 17/767,825 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1, 5-16, and 22 are anticipated by claims 1-10 of the reference application. Applicant's arguments filed January 23, 2026 have been fully considered but they are not persuasive. Applicant asserts that the Office Action does not appear to assert any basis for concluding that any of the pending claims are obvious over the ‘825 application by itself. The examiner respectfully disagrees. As set forth above and on page 5 of the Office Action dated October 23, 2025, claims 1, 5-16, and 22 are anticipated by claims 1-10 of the reference application. Thus, the rejection is maintained for the reasons of record as set forth in the Office Action dated October 23, 2025. Conclusion Claims 1-38 are pending. Claims 1, 5-16, and 22 are rejected. Claims 2-4, 17-21, and 23-38 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Contacts Any inquiry concerning this communication or earlier communications from the examiner should be directed to PATRICK T LEWIS whose telephone number is (571)272-0655. The examiner can normally be reached Monday to Friday, 10 AM to 4 PM EST (Maxi Flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PATRICK T LEWIS/Primary Examiner, Art Unit 1691 /PL/
Read full office action

Prosecution Timeline

Mar 23, 2023
Application Filed
Oct 23, 2025
Non-Final Rejection mailed — §112
Jan 23, 2026
Response Filed
May 19, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636305
COMPOSITION AND METHOD OF APPLYING SAME TO INCREASE SURVIVAL OF FISH FOLLOWING CATCH-AND-RELEASE SITUATIONS
3y 2m to grant Granted May 26, 2026
Patent 12629387
COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES
3y 8m to grant Granted May 19, 2026
Patent 12616778
COMPOSITE ULTRATHIN COATING FILM WITH INHIBITORY ACTIVITY AGAINST HYPERINFLAMMATORY RESPONSE AND BACTERIA, IMPLANT INCLUDING SAME, AND PREPARATION METHOD THEREFOR
2y 4m to grant Granted May 05, 2026
Patent 12606589
BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME
3y 9m to grant Granted Apr 21, 2026
Patent 12605397
DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES
2y 1m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
89%
With Interview (+14.5%)
2y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1146 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month